annb0t
Top 20
MELBOURNE, Australia, June 27, 2022 /PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that Dr. Paul Liknaitzky, Head of Clinical Psychedelic Research at Monash University and Chief Principal Investigator for Incannex's psilocybin-assisted psychotherapy, will present an...
>>> Read more: Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference
>>> Read more: Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference
